Triamterene and hydrochlorothiazide combines triamterene, a potassium-conserving diuretic, with the natriuretic agent, hydrochlorothiazide.
This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.
- Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.
- Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arryhthmias, etc.).
Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary.
Usage in Pregnancy
The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.
Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.
Published Studies Related to Triamterene and Hydrochlorothiazide (Triamterene / Hydrochlorothiazide)
Bioequivalence evaluation of a triamterene-hydrochlorothiazide generic product: a new bioequivalence index for fixed-dose combinations. [2011.02]
In this study, an open, double-blind, randomized, two-period, two-group crossover design was conducted in 14 healthy volunteers to study the bioequivalence of a fixed-dose generic product. After administration of test or reference products to each volunteer, both active ingredients were determined simultaneously in plasma samples using a developed and validated HPLC-UV method, and pharmacokinetic parameters, including C(max), T(max), AUC(0-t) , AUC(0infinity), terminal elimination rate constant (lambdaz), volume of distribution in steady state (Vd(ss)), mean residence time (MRT), clearance (Cl), terminal elimination rate constant (Kel) were determined in each subject using the standard non-compartmental approach...
Clinical Trials Related to Triamterene and Hydrochlorothiazide (Triamterene / Hydrochlorothiazide)
A Crossover Pilot Study of the Effect of Amiloride on Proteinuria [Recruiting]
This cross-over study is designed to test the hypothesis that amiloride will reduce urinary
protein excretion and protect the kidney from rapid progression in proteinuric kidney
Diuretics, Hypertension, and Arrhythmias Clinical Trial [Completed]
To determine whether hypertensive patients with ECG abnormalities and receiving
hydrochlorothiazide diuretics were at increased risk of sudden death.
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease [Enrolling by invitation]
The purpose of the study is to determine whether a diuretic drug called amiloride is capable
of increasing renal salt excretion and thereby decrease blood pressure in diabetic patients
with kidney disease. Our hypothesis states that amiloride is capable of reducing blood
pressure in these patients and thus decrease the cardiovascular risk associated with
diabetic kidney disease.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [Completed]
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke,
or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic
control, intensive blood pressure control, and multiple lipid management.
Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension [Completed]
Plasma renin values determine whether volume or vasoconstrictor (renin) factors predominate
in elevating blood pressure and are useful in selecting effective antihypertensive
The researchers hypothesize that:
1. Plasma renin-guided therapeutics will improve systolic and diastolic blood pressure
control in patients with untreated hypertension as well as in patients with treatment
refractory or resistant hypertension that are managed by Clinical Hypertension
2. Renin-guided therapeutics will reduce the number of medications required to maintain
blood pressure control to <140/90 mmHg in hypertensive patients receiving 3 or more
medications, while under the care of a Clinical Hypertension Specialist.
3. Renin-guided therapeutics selection will reduce the total cost of antihypertensive care
provided by Clinical Hypertension Specialists.
Reports of Suspected Triamterene and Hydrochlorothiazide (Triamterene / Hydrochlorothiazide) Side Effects
Completed Suicide (23),
Respiratory Arrest (11),
Cardiac Arrest (11),
Drug Ineffective (8),
Cardio-Respiratory Arrest (6),
Toxicity TO Various Agents (5),
Nephrolithiasis (4), more >>
Page last updated: 2011-12-09